Breaking Finance News

Bayer (ETR:BAYN) stock price target bumped up to 129.00EUR, released a ratings update today by Goldman Sachs Group Inc.

Boasting a price of 92.06EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. The last stock price is up -4.07% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of 0.04EUR and a 200-day moving average of 0.03EUR. 0 shares of the stock were exchanged, down from an average trading volume of 215

Bayer (ETR:BAYN) had its price target upped to 129.00EUR by Goldman Sachs Group Inc. in a report released 9/23/2016. The bumped up target indicates a possible upside of 0.40% from the company's most recent stock price close.

See Chart Below

Bayer (ETR:BAYN)

Bayer has a with a one year low of 0.03EUR and a one year high of 0.04EUR Bayer’s market capitalization is presently 0 EUR.

More About Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *